Mirum Pharmaceuticals, Inc. (“Mirum”) (NASDAQ:MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $200.0 million aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on April 17, 2023, subject to customary closing conditions.
Mirum expects to use the remaining net proceeds from this offering for general corporate purposes, including working capital, operating expenses and capital expenditures. Mirum may also use a portion of the net proceeds, together with existing cash, cash equivalents, restricted cash equivalents and short-term investments, to acquire complementary businesses, services or technologies.
